SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health ($OSCR) is trending after the House passed a bill to extend ACA subsidies, sparking intense community debate on its potential for future growth and profitability, with investors keenly focused on the upcoming earnings report and crucial 2026 guidance amidst broader healthcare sector sentiment.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv (FISV) is actively trending as investors keenly await its earnings report, fueling intense community debate between those who believe the stock is deeply undervalued with a promising turnaround under new leadership, and others bracing for a significant drop mirroring previous disappointments and broader fintech sector headwinds. Significant options activity indicates widespread expectation of a volatile price movement following the announcement.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following strong Q4 earnings and a new share buyback, prompting community debate over its significant stock-based compensation and dilutive practices, particularly as reports circulate about Meta's Instagram developing a rival app.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending amid a broad software sector sell-off, fueled by investor concerns that rapidly advancing AI will disrupt or replace traditional SaaS models. While some analysts and market participants argue that AI will enhance core enterprise software and point to a significant government contract, the community remains polarized between those calling it a "generational buying opportunity" and those fearing further valuation compression.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending due to its strong Q4 earnings beat and robust subscriber growth, alongside recent premium subscription price increases. The community is widely debating if these positive catalysts, coupled with new AI features and video content, can reverse the stock's recent downtrend and its perceived correlation with Netflix's performance, as many consider it oversold.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending due to the FDA's Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, citing concerns over trial design, including natural history controls and the surrogate endpoint. This decision has ignited community debate, with many investors anticipating a substantial stock drop and others expressing frustration over the FDA's stringent approach to rare disease gene therapies.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending following strong Q4 2025 financial results and positive FY26 guidance, bolstered by recent FDA approvals for its oncology blockbusters Enhertu and Datroway, and groundbreaking Phase 3 data for hypertension treatment Baxdrostat. The community is actively discussing the company's strategic direct listing on the NYSE, along with significant investments in US manufacturing and an expanding obesity pipeline in China, all signaling a robust long-term growth outlook.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork (UPWK) is trending sharply lower after providing a weaker-than-expected outlook, despite reporting a beat on its recent earnings. The community is actively debating if the platform is becoming obsolete due to advancing AI technology, while some view the sell-off as an overreaction and a buying opportunity.

Dynatrace, Inc. engages in the advancing observability for today’s digital businesses, helping to transform the complexity of modern digital ecosystems into powerful business assets. By leveraging AI-powered insights, Dynatrace enables organizations to analyze, automate, and innovate faster to drive their business forward. The company was founded by Bernd Greifeneder in 2005 and is headquartered in Boston, MA.

Dynatrace Inc

Dynatrace is trending following a strong earnings report for Q3 fiscal year 2026, which surpassed expectations across key metrics, alongside the authorization of a $1 billion share repurchase program, sparking community discussion about a potential turnaround.

Investment Managers Series Trust II - Tradr 2X Long CRML Daily ETF

Tradr 2X Long CRML Daily ETF

The Tradr 2X Long CRML Daily ETF ($CRMX) is actively trending following its recent launch, offering leveraged exposure to Critical Metals ($CRML) and its rare earth projects, with the community highly engaged in debate over its volatile performance and potential for significant moves.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

COMPASS Pathways (NASDAQ:CMPS) Stock Price Down 7.6% - Should You Sell?

COMPASS Pathways (NASDAQ:CMPS) Trading Down 7.6% - Should You Sell...

COMPASS Pathways Target of Unusually High Options Trading (NASDAQ:CMPS)

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) saw some unusual options trading on Friday. Investors bought 7,423 call options on the company. This is an increase of 152% compared...

Royal Bank Of Canada Increases COMPASS Pathways (NASDAQ:CMPS) Price Target to $21.00

Royal Bank Of Canada increased their target price on COMPASS Pathways from $16.00 to $21.00 and gave the stock an "outperform" rating in a research note on Friday...

COMPASS Pathways (NASDAQ:CMPS) Trading Down 5.5% - What's Next?

COMPASS Pathways (NASDAQ:CMPS) Trading Down 5.5% - Here's What Happened...

<ul><li>FDA has accepted the company's Investigational New Drug application for COMP360.</li><li>The latest update clears the way for a late-stage Phase 2b/3 clinical trial.</li><li>The company said prior Phase 2 data showed the treatment was generally well tolerated.</li></ul>Compass Pathways (CMPS), on Wednesday, said the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application for COMP360, a drug to treat post-traumatic stress disorder (PTSD). The latest update clears the way for a late-stage Phase 2b/3 clinical trial.The study will evaluate the efficacy, safety, and tolerability of COMP360, with a blinded 12-week phase followed by a long-term open-label extension. The company said prior Phase 2 data showed the treatment was generally well tolerated and delivered rapid, durable symptom improvement.&nbsp;Compass also highlighted ongoing FDA discussions around a potential rolling NDA submission for treatment-resistant depression, with additional Phase 3 data expected in 2026.“PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options. We believe COMP360 has the potential to transform the treatment landscape for PTSD and bring hope to those who need it most,” said Guy Goodwin, Chief Medical Officer at Compass Pathways.<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> was up over 5% in pre-market trading on Wednesday.Earlier this week, Compass Pathways entered its seventh strategic collaboration, partnering with Radial Health, a national network of interventional psychiatry practices.&nbsp;The agreement is aimed at developing scalable care models for COMP360 psilocybin treatment, if approved, across a wide range of U.S. mental health care settings.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for CMPS on Stocktwits turned 'bullish' from 'bearish' a day earlier.&nbsp;<img src="https://news.stocktwits-cdn.com/CMPS_jpg_0a063eb6f2.webp" alt="CMPS.jpg">One user expects the stock to climb to $15 over the next few days.<stembedurl>https://stocktwits.com/macrossluvsrobotech/message/641088236</stembedurl>The stock has gained nearly 60% this year.<a href="https://stocktwits.com/news-articles/markets/equity/why-did-first-solar-stock-fall-5-in-premarket-today/cmxyC2bR4cD">Read also: Why Did First Solar Stock Fall 5% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

CMPS Stock Climbs 5% In Premarket After FDA Clears PTSD Trial Path

The company highlighted ongoing FDA discussions around a potential rolling NDA submission for treatment-resistant depression, with additional Phase 3 data expected in 2026.

Equity

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA...

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic...

Simplify Asset Management Inc. Purchases Shares of 290,000 COMPASS Pathways PLC Sponsored ADR $CMPS

Simplify Asset Management Inc. acquired a new position in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) during the third quarter, according to the company in its most...

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine brokerages that are covering the stock, MarketBeat...

<ul class="summary-bullets"><li>With an estimated 51.5 million U.S. adults suffering from mental illness and the psychedelic drug market projected to grow at a 15% CAGR to nearly $13 billion by 2035</li><li>&nbsp;Both Compass Pathways and Mind Medicine are positioned to tap a massive unmet need.</li><li>Mind Medicine leads in retail sentiment, cash runway into 2028, and late-stage progress with MM120, while Compass Pathways’ COMP360 could reach the market sooner.</li></ul>After years on the fringes of mainstream medicine, psychedelic drugmakers are suddenly finding themselves in the spotlight.Shares of companies developing psychedelic-based therapies surged this year, buoyed by a gradual softening of regulatory resistance, growing political support, and a string of company-specific catalysts. Positive clinical trial readouts, renewed investor appetite, and a pickup in merger-and-acquisition chatter have all helped fuel momentum across the space.As optimism builds around the therapeutic potential of psychedelics to treat conditions ranging from depression to PTSD, two names have stood out among the pack: Compass Pathways and Mind Medicine. Here’s a closer look at how these two psychedelic high-fliers compare — and what’s driving their rise.<h2 class="st-heading-2">Psychedelics Turn Mainstream</h2>Stymied by regulatory roadblocks, research into hallucinogenic compounds remained largely dormant for decades. However, a gradual regulatory thaw and a growing mental-health crisis have sparked renewed scientific interest. Psychedelics such as psilocybin, MDMA, and LSD are moving into the mainstream of psychological research, backed by robust clinical trials and growing institutional support.&nbsp;The psychedelics drug market is expected to grow at a compounded annual growth rate (CAGR) of 15% to nearly $13 billion in 2035 from $3 billion in 2025,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html">according</a> to Business Research and Consulting Group Roots Analysis.<img src="https://news.stocktwits-cdn.com/Psychedelics_Market_png_7463be0aca.webp" alt="Psychedelics Market.png">Source: Roots AnalysisThe&nbsp;<a href="https://stocktwits.com/symbol/PSIL">AdvisorShares Psychedelics ETF (PSIL)</a> has outperformed the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, which tracks the broader S&amp;P 500 Index.<img src="https://news.stocktwits-cdn.com/PSIL_Vs_SPY_png_168a676f0b.webp" alt="PSIL Vs SPY.png">Source: Koyfin<h2 class="st-heading-2">What Has Turned The Tide?</h2>This class of drugs has received strong backing from high-profile personalities, including Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Martin Makary. Kennedy has previously&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mnmd-stock-soars-after-rfk-jr-confirmed-as-hhs-chief/ch5iJvpRH6">advocated</a> for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.As an extension, the FDA has accorded top priority to review MDMA and other psychedelics, even mulling accelerated approval for these drugs.&nbsp;Big pharma name AbbVie announced an agreement to acquire Gilgamesh Pharmaceuticals' novel psychedelic therapy candidate, bretisilocin, in August for up to $1.2 billion, lending credence to this class of medication. Atai, a biotech developing treatments for mental health, merged with Beckley Psytech, bringing Beckley's BPL-003, an investigational therapy for treatment-resistant depression (TRD) and alcohol use disorder (AUD), into its pipeline. ATAI Beckley’s stock has gained 220% this year.<h2 class="st-heading-2">Compass Pathways Vs. Mind Medicine</h2>Mind Medicine stock has returned about 110% year-to-date, compared with the 84% gain for Mind Medicine.<img src="https://news.stocktwits-cdn.com/MNMD_Vs_CMPS_png_35ac2a510a.webp" alt="MNMD Vs CMPS.png">Source: KoyfinThe primary draw for these stocks lies in the sheer size of the market opportunity. In a presentation, Mind Medicine highlighted that roughly 51.5 million adults in the U.S. are affected by mental illness, underscoring the vast and largely underserved demand for effective treatments.Mind Medicines’ lead candidate MM120 orally disintegrating tablet (ODT) is in late-stage trials for major depressive disorder (MDD). Topline data from the study is due in mid-2026. Delving into the upcoming catalysts, CEO Rob Barrow said in the third-quarter earnings release:<blockquote>“We plan to initiate Ascend, our second Phase 3 study in MDD, in mid-2026 and remain focused on advancing toward FDA submissions in both generalized anxiety disorder (GAD) and major depressive disorder (MDD). With multiple anticipated Phase 3 topline data readouts ahead, 2026 is set to be the most significant year in our history to date. ”</blockquote>Mind Medicine reported no revenue and a net loss of $67.3&nbsp;million for the three months ended Sept. 30, 2025. On the other hand, Compass Pathways’ net loss stood at $137.72 million for the September quarter,&nbsp;compared with a loss of $38.50 million a year&nbsp;earlier.London-based Compass Pathways’ lead candidate COMP360, a synthetic formulation of psilocybin that is in late-stage clinical trials for treating mental health conditions, primarily treatment-resistant depression (TRD). CEO Kabir Nath said in the earnings release that the company was moving up the expected launch timing for COMP360 in TRD by 9 to 12 months. The company&nbsp;intends to file for approval by the second half of 2026.&nbsp;<h2 class="st-heading-2">MNMD Vs. CMPS: Cash Position</h2>Mind Medicine has beefed up its cash position with a recent offering. It said its cash, cash equivalents, and investments as of September 30, 2025 ($209.1 million), along with the net proceeds of $242.8 million from the recently completed offering, will be sufficient to fund the operations into 2028. Meanwhile, Compass Pathways had a smaller cash reserve at a comparable point, but the company said it would be enough to fund operating expenses and capital expenditures through 2027.<img src="https://news.stocktwits-cdn.com/Cash_Position_Sufficient_For_Medium_Term_png_e0ea50d775.webp" alt="Cash_Position_Sufficient_For_Medium_Term.png">Source: Fiscal.ai<h2 class="st-heading-2">MNMD Vs. CMPS: How Retail’s Positioned</h2>Retail traders, however, are favorably disposed to Mind Medicine. On Stocktwits, retail sentiment toward the stock has been ‘bullish’ as of early Wednesday.<figure class="image"><img style="aspect-ratio:712/439;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_8_37_12_AM_png_3de00ad9f2.webp" alt="Screenshot 2025-12-24 at 8.37.12 AM.png" width="712" height="439"></figure>Compass Pathways, meanwhile, attracted ‘neutral’ sentiment among retailers, with sentiment showing volatility throughout the year.<figure class="image"><img style="aspect-ratio:721/436;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_8_39_54_AM_png_d4c6176ec9.webp" alt="Screenshot 2025-12-24 at 8.39.54 AM.png" width="721" height="436"></figure>According to Koyfin, the average analyst price target for Mind Medicine stock is $28.67, implying 105% upside potential. All 13 analysts covering the stock have either a ‘Buy’ or a ‘Strong Buy’ rating on the stock. Compass Pathways stock, meanwhile,&nbsp;has 144% upside potential, based on the average price target of $16.82. All but one of the 11 analyst covering the stock has bullish ratings.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-revamps-robotaxi-website-revamp-how-competition-stacks-up/cLesMvuREv3">Tesla Signals Robotaxi Expansion With Website Revamp — Here’s How The Competition Stacks Up</a>

 Creative image of an Hallucinogenic mushroom. (Representative image courtesy of Aitor Diago via Getty Images)

Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year?

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

CMPS
COMPASS Pathways

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CMPS News

CMPSCOMPASS Pathways